AU5383196A - Pharmaceutical compositions for prevention and treatment of central nervous system disorders - Google Patents

Pharmaceutical compositions for prevention and treatment of central nervous system disorders

Info

Publication number
AU5383196A
AU5383196A AU53831/96A AU5383196A AU5383196A AU 5383196 A AU5383196 A AU 5383196A AU 53831/96 A AU53831/96 A AU 53831/96A AU 5383196 A AU5383196 A AU 5383196A AU 5383196 A AU5383196 A AU 5383196A
Authority
AU
Australia
Prior art keywords
prevention
treatment
pharmaceutical compositions
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU53831/96A
Inventor
Merouane Bencherif
Balwinder Singh Bhatti
William Scott Caldwell
Peter Anthony Crooks
Niranjan Madhukar Deo
Gary Maurice Dull
Patrick Michael Lippiello
Alain Ravard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
RJ Reynolds Tobacco Co
Original Assignee
University of Kentucky Research Foundation
RJ Reynolds Tobacco Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/437,153 external-priority patent/US5583140A/en
Application filed by University of Kentucky Research Foundation, RJ Reynolds Tobacco Co filed Critical University of Kentucky Research Foundation
Publication of AU5383196A publication Critical patent/AU5383196A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU53831/96A 1995-05-17 1996-04-03 Pharmaceutical compositions for prevention and treatment of central nervous system disorders Abandoned AU5383196A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43715495A 1995-05-17 1995-05-17
US08/437,153 US5583140A (en) 1995-05-17 1995-05-17 Pharmaceutical compositions for the treatment of central nervous system disorders
US437154 1995-05-17
US437153 1995-05-17
PCT/US1996/004536 WO1996036637A1 (en) 1995-05-17 1996-04-03 Pharmaceutical compositions for prevention and treatment of central nervous system disorders

Publications (1)

Publication Number Publication Date
AU5383196A true AU5383196A (en) 1996-11-29

Family

ID=27031202

Family Applications (1)

Application Number Title Priority Date Filing Date
AU53831/96A Abandoned AU5383196A (en) 1995-05-17 1996-04-03 Pharmaceutical compositions for prevention and treatment of central nervous system disorders

Country Status (2)

Country Link
AU (1) AU5383196A (en)
WO (1) WO1996036637A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510459D0 (en) 1995-05-24 1995-07-19 Zeneca Ltd Bicyclic amines
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US20020052497A1 (en) 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
ES2218676T3 (en) * 1996-05-13 2004-11-16 Syngenta Limited BICYCLE AMINAS AS INSECTICIDES.
GB9623944D0 (en) * 1996-11-15 1997-01-08 Zeneca Ltd Bicyclic amine derivatives
GB9624611D0 (en) * 1996-11-26 1997-01-15 Zeneca Ltd Bicyclic amine compounds
WO1998025924A1 (en) 1996-11-26 1998-06-18 Zeneca Limited 8-azabicyclo[3.2.1]octane-, 8-azabicyclo[3.2.1]oct-6-ene-, 9-azabicyclo[3.3.1]nonane-, 9-aza-3-oxabicyclo[3.3.1]nonane- and 9-aza-3-thiabicyclo[3.3.1]nonane derivatives, their preparation and their use as insecticides
WO1998048801A1 (en) * 1997-04-26 1998-11-05 Sumitomo Pharmaceuticals Co., Ltd. 2-azabicyclo compounds
WO1999000385A1 (en) * 1997-06-30 1999-01-07 R.J. Reynolds Tobacco Company 3-pyridyl-1-aza-bicyclo-alkane derivatives for prevention and treatment of cns disorders
US6525065B1 (en) 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US5986100A (en) * 1998-04-02 1999-11-16 Crooks; Peter Anthony Pharmaceutical compositions and methods for use
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US7790757B2 (en) 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US20050131034A1 (en) 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
AU4230799A (en) * 1998-06-16 2000-01-05 Targacept, Inc. Aryl substituted olefinic amines and their use as cholinergic receptors agonists
JP2003501416A (en) * 1999-06-07 2003-01-14 ターガセプト，インコーポレイテッド Pharmaceutical compositions and uses thereof
PT1678172E (en) 2003-10-15 2010-03-03 Targacept Inc Azabicyclic compounds for relieving pain and treating central nervous system disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412798A3 (en) * 1989-08-08 1992-07-01 Merck Sharp & Dohme Ltd. Substituted pyridines, their preparation, formulations and use in dementia
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
AU7474794A (en) * 1993-07-22 1995-02-20 E.I. Du Pont De Nemours And Company Arthropodicidal azacyclic heterocycles
EP0717623A1 (en) * 1993-09-10 1996-06-26 Cytomed, Inc. Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists

Also Published As

Publication number Publication date
WO1996036637A1 (en) 1996-11-21

Similar Documents

Publication Publication Date Title
AU4645596A (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
AU2736097A (en) Method for preparation of compounds useful for prevention and treatment of central nervous system disorders
AU6974996A (en) Compositions for the treatment of dermatological disorders and methods for their use
AU4585996A (en) Pyrazolopyrimidines for treatment of neuronal and other disorders
HUP0100815A3 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
AU5383196A (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
HUP9701096A3 (en) Use of benzenesulfonamides for the preparation of pharmaceutical compositions treating disorders of the central nervous system, novel derivatives, process for their preparation and pharmaceutical compositions containing them
SI0751129T1 (en) Substituted dihydrodibenzo(b,f)azepines, method for their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
AU2053597A (en) Pharmaceutical compositions for the treatment of glaucoma
HUP9901707A3 (en) Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
AU4078997A (en) Cholinesterase inhibitors for treatment of parkinson's disease
AU5354394A (en) Beta -agonist, alpha1-agonist, and/or alpha2-antagonist treatment of neurodegenerative diseases and central nervous system trauma
PL316528A1 (en) Pharmaceutic compositions and drugs for prevetion and treatment of endothelial disorders
AU3681095A (en) Method and pharmaceutical composition for prevention and treatment of brain damage
AU2293992A (en) Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders
AU3151097A (en) Pharmaceutical for treating of neurological and neuropsychiatric disorders
AU2180097A (en) Composition for prevention and treatment of periodontal diseases
AU4674797A (en) Phenylalaninol derivatives for the treatment of central nervous system disorders
AU4151897A (en) Pharmaceutical compositions and methods of treating compulsive disorders using naaladase inhibitors
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
AU3046897A (en) Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
AU8369998A (en) Medicinal product and method for treatment and prevention of cognitive disorders
PL321630A1 (en) Application of melantonine for treting patients suffering from drug dependence
AUPN104895A0 (en) Methods of and preparations for the treatment of ailments and disorders